|
Video: What is a Stock Split?
|
|
Talaris Therapeutics is a late-clinical stage, cell therapy company developing a method of allogeneic hematopoietic stem cell transplantation (allo-HSCT) that has the potential to transform the standard of care in solid organ transplantation, certain severe autoimmune diseases and certain severe blood, immune and metabolic disorders. In the organ transplant setting, which it calls Facilitated Allo-HSCT Therapy, could prevent organ rejection without the morbidity. Co.'s primary product candidate, FCR001, which is central to its Facilitated Allo-HSCT Therapy, is an allogeneic cell therapy comprised of stem and immune cells that are procured from a healthy donor. According to our TALS split history records, Talaris Therapeutics has had 0 splits. | |
|
Talaris Therapeutics (TALS) has 0 splits in our TALS split history database.
Looking at the TALS split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Talaris Therapeutics shares, starting with a $10,000 purchase of TALS, presented on a split-history-adjusted basis factoring in the complete TALS split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
05/10/2021 |
|
End date: |
10/19/2023 |
|
Start price/share: |
$15.28 |
|
End price/share: |
$2.72 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-82.20% |
|
Average Annual Total Return: |
-50.65% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$1,780.10 |
|
Years: |
2.44 |
|
|
|
|
|